Preliminary efficacy and safety results of a new macular buckle model (NPB®) in myopic traction maculopathy.

PurposeTo describe the efficacy and safety outcomes of NPB^® macular buckle (MB) in myopic traction maculopathy (MTM).MethodsA monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with pars plana vitrectomy (PPV) for MTM, using the new NPB^® buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).ResultsForty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) "resolved" and 17 (43,6%) "improved" their retinal status, and 26 eyes (66,7%) "resolved", 8 (20,5%) "improved" and 5 (12,8%) "unchanged" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (p = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (p < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (p = 0,013), between the baseline and the final visit.ConclusionsThe new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.